ClinicalTrials.gg
Not yet recruitingNCT07728188Updated Jul 27, 2026

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of Etentamig and Pomalidomide in Relapsed or Refractory Multiple Myeloma, sponsored by AbbVie. Not yet recruiting at 66 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing etentamig in Multiple Myeloma — 6 open to participants now, 10 under way, 3 of them phase 3. etentamig · Multiple Myeloma.

Planned enrollment
3rd of 10
520 · median 235
Started
2026
with 2 others
Phase 3
2 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
9 of 10
AbbVie

Among the 10 studies testing etentamig in Multiple Myeloma, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2026, is one of 2 in phase 3, and was the 10th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 10 studies testing etentamig in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About etentamig

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing etentamig in Multiple Myeloma, or all of them as a file.
02

Study summary

Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide.

Etentamig is an investigational drug being developed for the treatment of relapsed or refractory multiple myeloma. This is a randomized, open-label study. The study will include a safety run-in portion and a randomized portion. The safety run-in participants will receive etentamig in combination with pomalidomide. The randomized portion of the study participants will receive either etentamig with pomalidomide or Standard Available Therapies (SATs). Approximately 520 participants will be enrolled in the study at approximately 200 sites worldwide.

Prior to initiation of the randomized portion of the study, the safety run-in will be conducted in which participants will receive etentamig injections plus oral pomalidomide. Following review of the safety run-in data and per protocol-defined criteria, the study will advance to the randomized portion where participants will be randomized to receive either etentamig injections plus oral pomalidomide or investigator's choice of SAT: SC daratumumab, oral pomalidomide, and oral/ IV dexamethasone (DPd); SC daratumumab, IV carfilzomib, and oral/IV dexamethasone (DKd); or SC teclistamab monotherapy. The total study duration is approximately 75 months

There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

Keywords

  • Relapsed or Refractory Multiple Myeloma
  • Etentamig
  • Pomalidomide
  • Cancer
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's planned enrollment of 520 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of (RR) multiple myeloma (MM).
  • Prior treatment with at least one and no more than three , including lenalidomide.
  • Adequate organ function and performance status

Exclusion criteria

Exclusion Criteria:

  • Prior B-cell maturation antigen (BCMA) directed T-cell engager therapy (bispecific or trispecific)
  • Known central nervous system involvement of MM
  • Known history of other active within the past 3 years (with specific exceptions)
  • conditions (renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
520 participants (estimated)

Study arms

  • Experimental
    Safety Run-In: Etentamig Plus Pomalidomide

    Participants will receive etentamig in combination with pomalidomide, as part of the approximately 75 month study duration.

    Drug: Etentamig · Drug: Pomalidomide

  • Experimental
    Randomized Portion: Etentamig Plus Pomalidomide

    Participants will receive etentamig in combination with pomalidomide, as part of the approximately 75 month study duration.

    Drug: Etentamig · Drug: Pomalidomide

  • Active comparator
    Randomized Portion: Standard Available Therapy (SAT)

    Participants will receive Investigator's choice of SATs: DPd, DKd, or teclistamab monotherapy as part of the 75 month study duration.

    Drug: Daratumumab · Drug: Dexamethasone · Drug: Carfilzomib · Drug: Teclistamab

Interventions

07

What researchers measure

Primary outcomes

  1. Safety Run-In: Number of Participants With Adverse Events (AE)s

    AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 75 Months

  2. Randomized Portion: Complete Response (CR) or Better Rate Per Independent Review Committee (IRC) Assessment

    CR or better is defined as proportion of participants with best overall response (BOR) of CR or stringent CR (sCR) as assessed per International Myeloma Working Group (IMWG) 2016 criteria. CR is defined as negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and less than 5% plasma cells in bone marrow aspirates. The treatment effect will be summarized as the difference in the CR or better rates between etentamig in combination with pomalidomide and standard available therapies (SAT).

    Time frame: Up to Approximately 75 Months

  3. Randomized Portion: Progression-Free Survival (PFS) Per Independent Review Committee (IRC) Assessment

    PFS is defined as duration from the date of randomization to the date of disease progression assessed according to the IMWG (2016) response criteria, per IRC assessment or death due to any cause, whichever occurs first.

    Time frame: Up to Approximately 75 Months

Secondary outcomes

  1. Safety Run-In: Best Overall Response (BOR) of Per Investigator Assessment

    BOR is defined as the best response achieved across all response assessments, partial response (PR) + very good partial response (VGPR) + complete response (CR) + stringent complete response (sCR), from randomization until disease progression per investigator assessment, using IMWG (2016) response criteria.

    Time frame: Up to Approximately 75 Months

  2. Safety Run-In: Maximum Observed Concentration (Cmax) of Etentamig

    Cmax of Etentamig.

    Time frame: Up to Approximately 12 Months

  3. Safety Run-In: Time to Cmax (Tmax) of Etentamig

    Cmax of Etentamig.

    Time frame: Up to Approximately 12 Months

  4. Safety Run-In: Area under the Serum Concentration-Time Curve (AUC) of Etentamig

    Cmax of Etentamig.

    Time frame: Up to Approximately 12 Months

  5. Safety Run-In: Immunogenicity of Etentamig

    Immunogenicity of etentamig is defined as the summary of antidrug antibody (ADA) status, ADA titers, and neutralizing antibody (NAb)s, if NAb samples are analyzed.

    Time frame: Up to Approximately 75 Months

  6. Randomized Portion: Minimal Residual Disease Negative Complete Response (MRDnegCR) Per IRC Assessment

    MRDnegCR is defined as achievement of CR or better by IMWG (2016) response criteria per IRC assessment and MRD negative status as assessed by next-generation sequencing (NGS) at threshold defined in the protocol.

    Time frame: Up to Approximately 75 Months

  7. Randomized Portion: Overall Survival (OS)

    Overall Survival (OS) is defined as the duration from the date of randomization to the date of death from any cause.

    Time frame: Up to Approximately 75 Months

  8. Randomized Portion: Sustained Minimal Residual Disease (MRD) Negativity

    Sustained MRD negativity assessed in participants with relapsed/refractory multiple myeloma (RRMM).

    Time frame: Up to Approximately 75 Months

  9. Randomized Portion: Best Minimal Residual Disease Negative Complete Response (MRD Negative CR) Per IRC Assessment

    Best MRD negative CR per IRC assessment in participants with relapsed/refractory multiple myeloma (RRMM).

    Time frame: Up to Approximately 75 Months

  10. Randomized Portion: BOR Per IRC Assessment

    BOR is defined as the best response achieved across all response assessments, PR + VGPR + CR +sCR from randomization until disease progression per IRC assessment, using IMWG (2016) response criteria.

    Time frame: Up to Approximately 75 Months

  11. Randomized Portion: VGPR or Better Rate Per IRC Assessment

    VGPR or better rate per IRC assessment, defined as percentage of participants achieving VGPR, CR, or sCR using IMWG (2016) response criteria.

    Time frame: Up to Approximately 75 Months

  12. Randomized Portion: Time to Response (TTR) Per IRC Assessment

    TTR is defined as the time from randomization to first documented response (PR or better) per IRC assessment using IMWG (2016) response criteria.

    Time frame: Up to Approximately 75 Months

  13. Randomized Portion: Duration of Response (DOR) Per IRC Assessment

    DOR is defined as the time from first documented response (PR or better) to disease progression or death, whichever occurs first, per IRC assessment using IMWG (2016) response criteria.

    Time frame: Up to Approximately 75 Months

  14. Randomized Portion: Second Progression-Free Survival (PFS2)

    PFS2 is defined as time from randomization to second disease progression or death from any cause, whichever occurs first.

    Time frame: Up to Approximately 75 Months

  15. Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life (QoL) Score

    Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life score. Patient-reported outcome (PRO) assessment.

    Time frame: Up to Approximately 75 Months

  16. Randomized Portion: Event-Free Survival (EFS) Per IRC Assessment

    EFS per IRC assessment in participants with relapsed/refractory multiple myeloma (RRMM).

    Time frame: Up to Approximately 75 Months

  17. Randomized Portion: Time to Next Treatment (TTNT)

    TTNT is defined as time from randomization to initiation of next anti-myeloma therapy.

    Time frame: Up to Approximately 75 Months

  18. Randomized Portion: Time to Symptomatic Disease Progression

    Time to symptomatic disease progression in participants with relapsed/refractory multiple myeloma (RRMM).

    Time frame: Up to Approximately 75 Months

  19. Randomized Portion: Change From Baseline in Disease Symptoms as Measured by the Disease Symptoms Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Myeloma Module (EORTC QLQ-MY20)

    Change from baseline in disease symptoms as measured by the disease symptoms domain of the EORTC QLQ-MY20 .

    Time frame: Up to Approximately 75 Months

  20. Randomized Portion: Change From Baseline in Physical Functioning as Measured by the Physical Functioning Domain of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    Change from baseline at 6 months in physical functioning as measured by the physical functioning domain of the EORTC QLQ-C30.

    Time frame: Up to Approximately 75 Months

  21. Randomized Portion: Overall Bother Due to Treatment Side Effects as Assessed by the Functional Assessment of Cancer Therapy - General Population, Item 5 (FACT-G GP5)

    Overall bother due to treatment side effects as assessed by the Functional Assessment of Cancer Therapy - General Population, Item 5 FACT-G GP5. Patient-reported outcome (PRO) assessment.

    Time frame: Up to Approximately 75 Months

08

Study locations

66 sites
09

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2033, 75 months later.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 75 months is above that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 27, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Feb 2033
CompletionEst.
Feb 2033
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07728188
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Feb 2033 (estimated)
Completion
Feb 2033 (estimated)
Last update
Jul 27, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Etentamig · Pomalidomide

Start the discussion